vs
Side-by-side financial comparison of CROSS COUNTRY HEALTHCARE INC (CCRN) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $236.8M, roughly 1.2× CROSS COUNTRY HEALTHCARE INC). CROSS COUNTRY HEALTHCARE INC runs the higher net margin — -35.0% vs -45.7%, a 10.7% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs -23.6%). CROSS COUNTRY HEALTHCARE INC produced more free cash flow last quarter ($16.1M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -21.0%).
GE Healthcare Technologies, Inc. is an American health technology company based in Chicago, Illinois. The company, which stylizes its own name as GE HealthCare, operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical ...
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
CCRN vs GH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $236.8M | $281.3M |
| Net Profit | $-82.9M | $-128.5M |
| Gross Margin | — | 64.6% |
| Operating Margin | -30.2% | -43.0% |
| Net Margin | -35.0% | -45.7% |
| Revenue YoY | -23.6% | 39.4% |
| Net Profit YoY | -2109.7% | -15.8% |
| EPS (diluted) | $-2.56 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $236.8M | $281.3M | ||
| Q3 25 | $250.1M | $265.2M | ||
| Q2 25 | $274.1M | $232.1M | ||
| Q1 25 | $293.4M | $203.5M | ||
| Q4 24 | $309.9M | $201.8M | ||
| Q3 24 | $315.1M | $191.5M | ||
| Q2 24 | $339.8M | $177.2M | ||
| Q1 24 | $379.2M | $168.5M |
| Q4 25 | $-82.9M | $-128.5M | ||
| Q3 25 | $-4.8M | $-92.7M | ||
| Q2 25 | $-6.7M | $-99.9M | ||
| Q1 25 | $-490.0K | $-95.2M | ||
| Q4 24 | $-3.8M | $-111.0M | ||
| Q3 24 | $2.6M | $-107.8M | ||
| Q2 24 | $-16.1M | $-102.6M | ||
| Q1 24 | $2.7M | $-115.0M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | 20.4% | 64.7% | ||
| Q2 25 | 20.4% | 65.0% | ||
| Q1 25 | 20.0% | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | 20.4% | 61.1% | ||
| Q2 24 | 20.8% | 59.1% | ||
| Q1 24 | 20.4% | 61.2% |
| Q4 25 | -30.2% | -43.0% | ||
| Q3 25 | -2.4% | -37.3% | ||
| Q2 25 | -2.1% | -45.9% | ||
| Q1 25 | -0.3% | -54.6% | ||
| Q4 24 | -1.1% | -62.4% | ||
| Q3 24 | 0.9% | -61.3% | ||
| Q2 24 | -5.7% | -56.8% | ||
| Q1 24 | 0.8% | -59.2% |
| Q4 25 | -35.0% | -45.7% | ||
| Q3 25 | -1.9% | -35.0% | ||
| Q2 25 | -2.4% | -43.0% | ||
| Q1 25 | -0.2% | -46.8% | ||
| Q4 24 | -1.2% | -55.0% | ||
| Q3 24 | 0.8% | -56.3% | ||
| Q2 24 | -4.7% | -57.9% | ||
| Q1 24 | 0.7% | -68.2% |
| Q4 25 | $-2.56 | $-1.01 | ||
| Q3 25 | $-0.15 | $-0.74 | ||
| Q2 25 | $-0.20 | $-0.80 | ||
| Q1 25 | $-0.02 | $-0.77 | ||
| Q4 24 | $-0.13 | $-0.90 | ||
| Q3 24 | $0.08 | $-0.88 | ||
| Q2 24 | $-0.47 | $-0.84 | ||
| Q1 24 | $0.08 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $108.7M | $378.2M |
| Total DebtLower is stronger | — | $1.5B |
| Stockholders' EquityBook value | $322.8M | $-99.3M |
| Total Assets | $449.0M | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.7M | $378.2M | ||
| Q3 25 | $99.1M | $580.0M | ||
| Q2 25 | $81.2M | $629.1M | ||
| Q1 25 | $80.7M | $698.6M | ||
| Q4 24 | $81.6M | $525.5M | ||
| Q3 24 | $64.0M | $585.0M | ||
| Q2 24 | $69.6M | $933.7M | ||
| Q1 24 | $5.2M | $1.0B |
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $322.8M | $-99.3M | ||
| Q3 25 | $408.1M | $-354.5M | ||
| Q2 25 | $412.2M | $-305.5M | ||
| Q1 25 | $418.2M | $-250.8M | ||
| Q4 24 | $419.0M | $-139.6M | ||
| Q3 24 | $424.7M | $-60.1M | ||
| Q2 24 | $433.3M | $-1.6M | ||
| Q1 24 | $462.4M | $68.3M |
| Q4 25 | $449.0M | $2.0B | ||
| Q3 25 | $538.2M | $1.3B | ||
| Q2 25 | $553.8M | $1.3B | ||
| Q1 25 | $576.2M | $1.3B | ||
| Q4 24 | $589.3M | $1.5B | ||
| Q3 24 | $597.4M | $1.5B | ||
| Q2 24 | $602.9M | $1.6B | ||
| Q1 24 | $648.4M | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.2M | $-26.4M |
| Free Cash FlowOCF − Capex | $16.1M | $-54.2M |
| FCF MarginFCF / Revenue | 6.8% | -19.3% |
| Capex IntensityCapex / Revenue | 0.9% | 9.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $40.1M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.2M | $-26.4M | ||
| Q3 25 | $20.1M | $-35.4M | ||
| Q2 25 | $4.2M | $-60.3M | ||
| Q1 25 | $5.7M | $-62.7M | ||
| Q4 24 | $24.2M | $-64.5M | ||
| Q3 24 | $7.5M | $-51.1M | ||
| Q2 24 | $82.4M | $-94.0M | ||
| Q1 24 | $6.0M | $-30.3M |
| Q4 25 | $16.1M | $-54.2M | ||
| Q3 25 | $17.9M | $-45.8M | ||
| Q2 25 | $2.3M | $-65.9M | ||
| Q1 25 | $3.8M | $-67.1M | ||
| Q4 24 | $21.7M | $-83.4M | ||
| Q3 24 | $6.3M | $-55.3M | ||
| Q2 24 | $79.6M | $-99.1M | ||
| Q1 24 | $3.8M | $-37.2M |
| Q4 25 | 6.8% | -19.3% | ||
| Q3 25 | 7.2% | -17.3% | ||
| Q2 25 | 0.8% | -28.4% | ||
| Q1 25 | 1.3% | -33.0% | ||
| Q4 24 | 7.0% | -41.3% | ||
| Q3 24 | 2.0% | -28.9% | ||
| Q2 24 | 23.4% | -55.9% | ||
| Q1 24 | 1.0% | -22.1% |
| Q4 25 | 0.9% | 9.9% | ||
| Q3 25 | 0.9% | 3.9% | ||
| Q2 25 | 0.7% | 2.4% | ||
| Q1 25 | 0.6% | 2.2% | ||
| Q4 24 | 0.8% | 9.4% | ||
| Q3 24 | 0.4% | 2.2% | ||
| Q2 24 | 0.8% | 2.9% | ||
| Q1 24 | 0.6% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.92× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.23× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CCRN
| Temporary Staffing Services | $189.6M | 80% |
| Physician Staffing | $42.5M | 18% |
| Other Services | $4.7M | 2% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
